Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns

Company Overview - Hims & Hers (NYSE: HIMS) is a company leveraging the trend of telehealth to provide easier access to healthcare services [1] - The company's business model is under scrutiny for its durability and competitive advantage [1] Analyst Background - Oliver Rodzianko is an investment analyst specializing in the technology sector, with expertise in AI, semiconductors, software, and renewable energy [1] - He focuses on companies with resilient management and lasting competitive advantages [1] - Rodzianko's investment strategy involves value trading at inflection points without leverage or short interest, typically holding investments for one to two years [1] - He employs advanced risk-mitigation strategies to protect against and capitalize on recessions and market crashes [1]